Regen BioPharma, Inc. to Present at the Emerging Growth Conference on May 9, 2024 May 7, 2024 02:44PM
Regen BioPharma, Inc. to Discuss Plans to Move Forward with HemaXellerate into Clinical Phase 1 at the Emerging Growth Conference on April 4, 2024 Apr 2, 2024 09:30AM
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on March 7, 2024 Mar 5, 2024 08:30AM
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 7, 2024 Feb 5, 2024 07:00AM
Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 10, 2024 Jan 8, 2024 08:00AM
View Older Stories

Dec 5, 2023 09:00AM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 7, 2023
Nov 16, 2023 09:00AM Regen BioPharma, Inc. Selects Contract Research Organization to Assist in DuraCAR Experiments
Nov 14, 2023 09:00AM Regen BioPharma, Inc. CEO Outlines Future Steps in CAR T Program
Oct 30, 2023 09:30AM Regen BioPharma, Inc. to Discuss Confirmation Study Results on Its DuraCar Program at the Emerging Growth Conference on November 1, 2023
Oct 25, 2023 09:30AM Regen BioPharma, Inc. Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program
Sep 19, 2023 09:00AM Studies On Regen BioPharma, Inc.'s DURACAR Indicate Potential Suppression Of Autoimmunity, Company Retains Contract Research Organization To Conduct Additional Confirmatory Studies
Sep 6, 2023 09:00AM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on September 6, 2023
Aug 8, 2023 09:30AM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on August 10, 2023
Feb 21, 2023 09:30AM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 22, 2023
Feb 21, 2023 07:00AM Presenting on the Emerging Growth Conference on February 22 Register Now
Feb 7, 2023 02:16PM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on February 8, 2023
Feb 7, 2023 07:00AM Presenting on the Emerging Growth Conference on February 8 Register Now
Jan 23, 2023 02:46PM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on January 25, 2023
Jan 20, 2023 04:10PM Regen BioPharma Leverages Exosome Technologies to Broaden its Survivin Cancer Immunotherapy Portfolio
Jan 9, 2023 12:41PM Regen BioPharma, Inc. to address 2023 goals and company direction at the Emerging Growth Conference on January 11, 2023
Dec 19, 2022 04:58PM Regen BioPharma, Inc. issues Message to the Shareholders from the Chairman And Chief Executive Officer
Dec 12, 2022 03:13PM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on December 14, 2022
Dec 7, 2022 10:00AM Regen BioPharma Appoints Two New Scientific Advisory Board Members
Nov 28, 2022 02:49PM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 30, 2022
Nov 18, 2022 08:00AM Regen BioPharma, Inc. Progresses Its DuraCAR Therapeutic
Nov 10, 2022 05:47PM Regen BioPharma Developing a Non-Exhaustible CAR-T Cell Therapeutic
Nov 2, 2022 11:13AM Regen BioPharma, Inc. to Present at the Emerging Growth Conference on November 9, 2022
Oct 26, 2022 10:49AM Regen BioPharma, Inc. Explores the CAR-T Therapeutic Space
Oct 5, 2022 02:17PM Regen BioPharma, Inc. Files Provisional Patent on CAR-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer
Sep 13, 2022 03:09PM Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy
Aug 25, 2022 02:11PM Regen BioPharma Develops Novel Means of Using CAR-T cell Immunotherapy to Attack Solid Tumors
Aug 11, 2022 03:06PM Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors
Jul 26, 2022 05:14PM Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine
Mar 16, 2022 03:16PM Regen BioPharma, Inc. Responds to Numerous Requests for Updates on its Intellectual Property (IP) Portfolio
Mar 10, 2022 07:00AM Regen BioPharma, Inc. Announces Program to Fast-Track its Checkpoint Inhibitor Program Utilizing Modified mRNA and siRNA Technologies
Oct 24, 2016 08:00AM Pan Am Cancer Treatment Center Provides Final HemaXellerate Clinical Data to Regen BioPharma, Inc. for treatment of Bone Marrow Suppression Study
Aug 16, 2016 08:00AM Regen BioPharma, Inc. Receives New Preliminary HemaXellerate Clinical Data on Bone Marrow Suppression from Pan Am Cancer Treatment Center
Jul 27, 2016 08:00AM Regen BioPharma, Inc. Files Composition of Matter Patent Application on NR2F6 Modulating Small Molecules
Jun 30, 2016 08:00AM Regen BioPharma, Inc. Enters Into Open Innovation Drug Discovery Program Agreement with Eli Lilly and Company
Jun 16, 2016 08:00AM Regen BioPharma, Inc.'s CEO Discusses and Clarifies the Potential of the NR2F6 Activator Program
Jun 14, 2016 08:30AM Regen BioPharma, Inc.'s Small Molecule Drug Screening Program Uncovers Activators of NR2F6
Jun 2, 2016 07:00AM Regen BioPharma, Inc. Discusses Its Major Small Molecule Drug Screening Program Targeting Immune Checkpoint NR2F6
Jun 1, 2016 09:23AM Regen BioPharma, Inc. Uplisted to Trade Publicly on OTCQB
May 24, 2016 07:00AM Regen BioPharma, Inc. Files Application to Trade Publicly on OTCQB
May 19, 2016 07:00AM Regen BioPharma, Inc. Announces ucVax: Universal Donor Cancer Cellular Immunotherapy
May 11, 2016 07:00AM Regen BioPharma, Inc. Discusses Recent Developments in Aplastic Anemia Therapy and Future Potential Expansion of HemaXellerate
May 3, 2016 07:00AM Regen BioPharma Receives Preliminary Clinical Data from Pan Am Cancer Center Regarding Their HemaXellerate Study in Cancer Patients
Apr 28, 2016 07:00AM Regen BioPharma's HemaXellerate Therapy for Treating Aplastic Anemia Licensed for Proof of Concept Study
Apr 21, 2016 07:00AM Regen BioPharma, Inc. Series A Preferred Stock Begins Trading Under the Symbol RGBPP on the OTC PINK
View Older Stories